180 North LaSalle Street
Suite 1600
Chicago, IL 60601
United States
844 445 5704
https://www.xerispharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 377
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Paul R. Edick | Chairman & CEO | 1,21M | N/D | 1956 |
Mr. John P. Shannon | President & COO | 918,15k | N/D | 1962 |
Mr. Steven M. Pieper | Chief Financial Officer | 681,14k | N/D | 1978 |
Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 695,44k | N/D | 1964 |
Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior VP of Global Development & Medical Affairs | 596,97k | N/D | 1963 |
Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Mr. Kevin McCulloch | Chief Commercial Officer | N/D | N/D | N/D |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
L'ISS Governance QualityScore di Xeris Biopharma Holdings, Inc. al 1 giugno 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 7.